Prateek Sharma, MD, FASGE reviewing Mehta RS, et al. Gastroenterology 2023 Sep.

Two recently published studies have evaluated the association between proton pump inhibitor (PPI) use and dementia—with divergent conclusions. This article reviews the study that investigated the potential associations between PPIs and histamine-2 receptor antagonists and dementia and cognitive impairment.

Prateek Sharma, MD, FASGE reviewing Northuis C, et al. Neurology 2023 Aug 9.

Divergent conclusions were made in two recently published studies that evaluated the association between proton pump inhibitor (PPI) use and dementia. This article reviews the study that investigated incident dementia in patients at a fifth visit, when PPI use was more common.

David H. Bruining, MD, FASGE reviewing Hedrick TL, et al. Clin Gastroenterol Hepatol 2023 Jul 25.

Clinicians frequently care for patients with enteral ostomies related to a diverse range of GI conditions, including colorectal cancer, trauma, diverticulitis, and inflammatory bowel disease. This practice update by the American Gastroenterological Association explores new data and provides expert opinion on managing complex issues related to enteral stomas.

Gursimran S. Kochhar, MD reviewing Gupta A, et al. Clin Gastro Hepatol 2023 Aug 12.

Many patients with inflammatory bowel disease, rheumatoid arthritis, and immune-mediated diseases are being diagnosed with age-related malignancies. Immune suppressive therapies help manage these diseases; however, patients and clinicians are concerned with possible malignancy relapse. A recently published meta-analysis addresses this concern.

Bincy P. Abraham, MD, MS reviewing Bokemeyer B, et al. Inflamm Bowel Dis 2023 Jul 31.

Although head-to-head studies between vedolizumab and adalimumab have shown the superiority of vedolizumab in treating ulcerative colitis, no such randomized controlled trial comparing the two agents exists for Crohn’s disease. This observational, prospective, noninterventional registry study evaluated bio-naïve patients with Crohn’s disease who started therapy with vedolizumab or the anti-tumor necrosis factors adalimumab or infliximab.